Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERT-IJS vs EU-Perjeta in HER2+ Breast Cancer
NCT06038539Phase 3Terminated
- Sponsor
- Biocon
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of PERT-IJS in breast cancer, sponsored by Biocon. Started Jan 2025; status: terminated.
02
Drugs
PERT-IJS
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06038539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038539.